Canine models have many advantages for evaluating therapy of human central nervous
system (CNS) diseases. In contrast to nonhuman primate models, naturally occurring canine …

Several neurodevelopmental and neurodegenerative disorders affecting the central nervous
system are potentially treatable via viral vector-mediated gene transfer. Adeno-associated …

Adeno-associated viral (AAV) vectors have become the primary delivery agent for somatic
gene transfer into the central nervous system (CNS). To date, AAV-mediated gene delivery …

Recombinant adeno-associated virus serotype 2 (rAAV2) vectors have shown promise as
therapeutic agents for neurologic disorders. However, intracerebral administration of this …

Vectors derived from adeno-associated virus (AAV) are promising candidates for neural cell
transduction in vivo because they are nonpathogenic and achieve long-term transduction in …

Adeno-associated virus (AAV) vectors have become an important tool for delivering
therapeutic genes for a wide range of neurological diseases. AAV serotypes possess …

Adeno-associated virus (AAV) vectors exhibit a number of properties that have made this
vector system an excellent choice for both CNS gene therapy and basic neurobiological …

Adeno-associated virus (AAV) vectors exhibit a number of properties that have made this
vector system an excellent choice for both CNS gene therapy and basic neurobiological …

Recombinant adeno-associated virus serotype 2 (rAAV2) vectors have been shown to
deliver genes effectively to neurons in the brain, retina, and spinal cord. The characterization …

Recombinant adeno-associated virus vectors based on serotype 2 (rAAV2) can direct
transgene expression in the central nervous system (CNS), but it is not known how other …